Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Conditions
Interventions
NYX-2925 50 mg
Placebo
Locations
35
United States
Aptinyx Clinical Site
Fresno, California, United States
Aptinyx Clinical Site
Irvine, California, United States
Aptinyx Clinical Site
Lomita, California, United States
Aptinyx Clinical Site
Los Angeles, California, United States
Aptinyx Clinical Site
Norco, California, United States
Aptinyx Clinical Site
Pomona, California, United States
Start Date
November 12, 2019
Primary Completion Date
February 23, 2022
Completion Date
February 23, 2022
Last Updated
April 28, 2023
NCT07285018
NCT06221241
NCT07377721
NCT06614322
NCT05177094
NCT06122012
Lead Sponsor
Aptinyx
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions